Three Days Away: The FDA Is About to Rule on the First New Quit-Smoking Drug in 20 Years

On June 20, three days from today, the Food and Drug Administration is scheduled to issue its ruling on cytisinicline — a plant-derived alkaloid that would become, if approved, the first new treatment for nicotine dependence to reach the market in two decades. The drug’s PDUFA date has been circled in oncology and addiction medicine calendars since Achieve Life Sciences submitted its New Drug Application in June 2025. The FDA accepted the application in September. What happens Friday determines whether the nicotine-dependence treatment landscape — which has been static since varenicline (Chantix) arrived in 2006 — finally gets a new option.

Twenty years is a long time in pharmacology. It is also a precise measure of how neglected nicotine treatment has been as a research priority, even as roughly 28 million Americans continue to smoke and vaping, which arrived with barely any cessation infrastructure to support people trying to quit, has spread to millions more.

What cytisinicline is — and where it comes from

Cytisinicline is not synthetic. It is an alkaloid derived from the seeds of the golden rain tree (Laburnum anagyroides), a plant native to central and southern Europe. The alkaloid has been used as a smoking cessation aid in Eastern Europe under the brand name Tabex since the 1960s, making it one of the older cessation interventions in existence — just not one the FDA has ever reviewed until now.

Its mechanism is closely related to varenicline (Chantix): both work as partial agonists at the α4β2 nicotinic acetylcholine receptor, the primary receptor site through which nicotine delivers its reinforcing effects. Partial agonism means the drug activates the receptor at a reduced intensity — enough to blunt withdrawal symptoms and cravings, not enough to deliver the full reward signal that sustains addiction. Where cytisinicline differs from varenicline is in its receptor selectivity profile. A March 2026 paper in Nicotine & Tobacco Research by Achieve Life Sciences researchers described a selectivity profile that the company argues explains the drug’s low nausea rates compared to earlier smoking cessation agents. Nausea was the primary tolerability problem with varenicline that led many patients to discontinue — a tolerability failure that limits a drug’s real-world effectiveness regardless of what the clinical trials show.

The FDA granted cytisinicline Breakthrough Therapy designation, a status reserved for drugs that show substantial improvement over existing therapies for serious conditions. That designation reflects both the strength of the efficacy data and the acknowledged unmet need — the “no new treatments in 20 years” gap.

What the trials showed

The ORCA-2 and ORCA-3 Phase 3 studies enrolled more than 2,000 participants across both trials and compared cytisinicline against placebo for smoking cessation in adults. Both trials showed that cytisinicline significantly increased continuous smoking abstinence compared to placebo, meeting their primary endpoints. The effect sizes were meaningfully above placebo — the trials were powered for a real efficacy signal, not a marginal one.

The tolerability data is what distinguishes this drug from its predecessors in the addiction treatment community’s practical calculation. Cessation drugs are only as useful as their completion rates. A drug that works in clinical trials but produces adverse effects severe enough to drive discontinuation is, in practice, a partial solution. Varenicline’s nausea and — controversially, and with evidence that was later revised — its behavioral side effects led to significant prescribing caution in the years after its approval. Cytisinicline’s receptor selectivity profile may translate into better real-world adherence, which is ultimately what determines population-level impact.

The FDA doesn’t approve drugs on mechanism alone. It approves them based on the totality of evidence, which in this case includes two completed Phase 3 trials, an open-label safety study, and the Breakthrough Therapy designation backing from an earlier clinical interaction. The PDUFA date is not a formality — the FDA can and does miss PDUFA dates, request additional information, or issue a complete response letter rather than an approval. But the application was accepted for review with the standard six-month timeline, which signals the filing was sufficiently complete to proceed.

But the application was accepted for review with the standard six-month timeline, which signals the filing was sufficiently complete to proceed.

The vaping gap — and why cytisinicline may matter even more there

There are no FDA-approved treatments for vaping cessation. None. Not a single pharmacological option has been reviewed and approved for the specific indication of nicotine dependence in people who vape rather than smoke. This matters because the vaping population — particularly younger users who may have started with a vape rather than a cigarette, for whom the psychological texture of nicotine dependence may be different, and who are often not captured by the epidemiological frameworks built for combustible tobacco — has been left with off-label options or nothing.

Achieve Life Sciences completed a Phase 2 study of cytisinicline in vaping cessation and, significantly, received an FDA Commissioner’s National Priority Voucher for the vaping cessation indication. That voucher accelerates the regulatory review pathway and reflects a recognition that vaping cessation is an unmet medical need with public health urgency. The company has conducted a successful end-of-Phase 2 meeting with the FDA to plan a Phase 3 vaping trial.

This means that if cytisinicline is approved on Friday for smoking cessation, it arrives not just as a new treatment for an old problem but as the infrastructure on which a separate and overdue vaping cessation development program is being built. The vaping-cessation indication would come later — Phase 3 trials still need to run — but the compound, the safety database, and the FDA relationship would already be in place.

The psychology of quitting, and why the treatment gap matters clinically

Nicotine is among the most pharmacologically reinforcing substances studied. The neurobiological basis is well understood: nicotine binds to acetylcholine receptors in the brain’s reward circuits, triggering dopamine release in the nucleus accumbens with a speed and reliability that most other substances don’t match. The behavioral reinforcement is compounded by the thousands of daily repetitions — a pack-a-day smoker takes roughly 200 puffs of nicotine over 24 hours — that encode the habit at a level deeper than pharmacology alone. This is why cessation is difficult and why relapse rates after unaided quit attempts run above 95 percent within the first year.

The psychological dimension of nicotine withdrawal — anxiety, irritability, difficulty concentrating, sleep disruption, mood dysregulation — is often underappreciated in settings focused on the physical health consequences of tobacco. For many people trying to quit, the cognitive and emotional disruption of withdrawal is the primary barrier. This is what partial agonist therapy addresses pharmacologically: it modulates the withdrawal experience enough to make sustained abstinence psychologically possible, not just pharmacologically assisted. The mechanism doesn’t eliminate the psychological work. It lowers the floor enough that the work becomes accessible.

Twenty years without a new pharmacological option in that category is not a minor gap. It is a structural absence in the treatment landscape for one of the most prevalent addictions in the country.

What happens Friday

If the FDA approves cytisinicline on or around June 20, 2026 — which the PDUFA date makes theoretically possible, though the agency often takes the full review period — the practical effects will take time to reach patients. The drug needs commercial manufacturing, prescriber education, formulary placement by payers, and patient-facing communication. Approval is not immediate access. The pipeline from PDUFA date to prescription pad runs through months of logistics.

But the approval itself represents a meaningful shift in the conversation: a new option exists, new prescribers will become familiar with it, and the vaping cessation program that depends on this compound’s safety database moves to its next phase. For the estimated 28 million Americans who still smoke and the millions more trying to quit vaping, treatment access on this indication has been at a standstill for two decades. That standstill may end Thursday night.

The Rize newsroom will cover the FDA ruling as it lands.

---

This post is part of the nicotine and tobacco substance coverage. Follow science and medicine for FDA decisions and addiction pharmacology updates.